A Study to Evaluate LY01011 and Xgeva® in Healthy Adults

NCT04198636 ↗

Phase 1 Unknown 168 enrolled Luye Pharma Group Ltd. Shandong Boan Biotechnology Co., Ltd · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blind, single-dose, parallel-group study to compare the pharmacokinetics, pharmacodynamics, safety and immunogenicity of LY01011 and Xgeva® in healthy adults

Timeline

Start: 2019-12-16
Primary completion: 2020-12-31
Completion: 2021-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Denosumab	Monoclonal antibody	120 mg	Subcutaneous
Subject	LY01011	Monoclonal antibody	120 mg	Subcutaneous

Indications

No indication recorded.